BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
水曜日, 9 30

Vivos Therapeutics Inc

VVOSNASDAQ
Trade with Public
Trade with Public
$0.1505
0.016412.23%
近くで: Sep 28, 5:00 PM EST
$0.1462
0.01219.02%
プレマーケット: 5:44 AM EST
PRO
なぜ動いているのか？:Vivos Therapeutics shares are trading higher after the company announced th...
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

Vivos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vivos Therapeutics (VVOS).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$4Upside to Avg. PT+2547.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Jun 4, 2026Ascendiant CapitalLucas WardPT RaiseBuy$3→$3
Apr 22, 2026Ascendiant CapitalLucas WardPT CutBuy$6→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See analyst ratings page for full details.
Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.
Benzinga Newsdesk

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved